PROTACs in Antivirals: Current Advancements and Future Perspectives
Molecules · 18.08.2025 · 30 (16) · 3402
DOI: 10.3390/molecules30163402 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 18.08.2025. Verfasst von Jiacheng Jin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou 310013, China. Hauptthemen laut MEDLINE: Antiviral Agents, Proteolysis, COVID-19 Drug Treatment. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: College Students’ Innovation Training Program of Zhejiang Province, Scientific and Technological Innovation (Xinmiao Talents) Program of Zhejiang Province, Health Commission of Zhejiang Province.
Abstract (Originalsprache)
Proteolysis-targeting chimera (PROTAC) technology has demonstrated remarkable progress in tumor therapy, attributed to its unique capability of catalytically degrading “undruggable” targets. In the context of the ongoing global health threat posed by the Coronavirus Disease 2019 (COVID-19) pandemic, the application scope of PROTAC technology has been gradually extended to the field of antiviral research. Unlike traditional small molecule inhibitors, PROTAC employs an “event-driven” mechanism to achieve ubiquitination-mediated degradation of target proteins. This approach holds great promise in addressing challenges such as drug resistance, targeting host-dependent factors, and high-mutagenic viral proteins. This article provides a comprehensive review of the application progress of PROTAC technology in antiviral therapy, with a particular emphasis on successful cases across a range of viral pathogens, including Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), influenza virus, and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Additionally, it delves into the challenges encountered in this field and ponders future development directions. Through the integration of the latest research findings, this article proposes a dual-target degradation strategy based on the host–pathogen interaction interface. These proposals aim to offer theoretical support for the clinical translation of antiviral PROTACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou 310013, China.
- Yongkang First People's Hospital, Yongkang 321306, China.
ORCID-Profile: Zunyuan Wang
Förderung
- College Students’ Innovation Training Program of Zhejiang Province
- Scientific and Technological Innovation (Xinmiao Talents) Program of Zhejiang Province
- Health Commission of Zhejiang Province
Zitieren
APA
Jin, J., Quan, M., Cao, X., Zhang, Y., Xu, X., & Wang, Z. (2025). PROTACs in Antivirals: Current Advancements and Future Perspectives. Molecules, 30(16), 3402. https://doi.org/10.3390/molecules30163402
Vancouver
Jin J, Quan M, Cao X, Zhang Y, Xu X, Wang Z. PROTACs in Antivirals: Current Advancements and Future Perspectives. Molecules. 2025;30(16):3402. doi:10.3390/molecules30163402
BibTeX
@article{Jin2025,
author = {Jin, Jiacheng and Quan, Mengxiang and Cao, Xueyan and Zhang, Yun and Xu, Xiangwei and Wang, Zunyuan},
title = {PROTACs in Antivirals: Current Advancements and Future Perspectives},
journal = {Molecules},
year = {2025},
volume = {30},
number = {16},
pages = {3402},
doi = {10.3390/molecules30163402}
}
EUVIMED